The prognostic and predictive impact of circulating tumour DNA (ctDNA) dynamics in patients with metastatic Triple Negative Breast Cancer (TNBC) on olaparib based therapy: Results from Cohort E of the PlasmaMATCH trial

被引：0
|
作者：
Browne, Iseult
Pascual, Javier
Cutts, Rosalind
Kingston, Belinda
Hrebien, Sarah
Kilburn, Lucy
Pearson, Alex
Moretti, Laura
Wardley, Andrew
Macpherson, Iain
Baird, Richard
Roylance, Rebecca
Faull, Iris
Banks, Kimberly C.
Garcia-Murillas, Isaac
Bliss, Judith
Ring, Alistair
Turner, Nicholas
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PS06-04
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PS06-04
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Circulating Tumor DNA and Biomarker Analyses From the LOTUS Randomized Trial of First-Line Ipatasertib and Paclitaxel for Metastatic Triple-Negative Breast Cancer
    Wongchenko, Matthew J.
    Kim, Sung-Bae
    Saura, Cristina
    Oliveira, Mafalda
    Lipson, Doron
    Kennedy, Mark
    Greene, Mandy
    Breese, Virginia
    Mani, Aruna
    Xu, Na
    Dent, Rebecca
    JCO PRECISION ONCOLOGY, 2020, 4 : 1012 - 1024
  • [42] Mutational profile from circulating tumor DNA in triple negative breast cancer: Results from the prospective registry of unresectable locally advanced or metastatic breast cancer GEICAM/2014-03 (RegistEM)
    Guerrero-Zotano, Angel
    Jara, Carlos
    Lopez-Tarruella, Sara
    Rodriguez, Cesar A.
    Adrover, Encarna
    Falo, Catalina
    Martinez, Purificacion
    Antolin, Silvia
    Margeli, Mireia
    Cruz, Josefina
    Rodriguez-Lescure, Alvaro
    Iranzo, Vega
    Gomez-Raposo, Cesar
    Juan Illarramendi, Jose
    Malon, Diego
    Luis Alonso, Jose
    Anton, Antonio
    Andres, Raquel
    Herranz, Jesus
    Bezares, Susana
    Caballero, Rosalia
    Alvarez, Isabel
    Rojo, Federico
    CANCER RESEARCH, 2021, 81 (04)
  • [43] Prognostic impact of circulating tumor cell apoptosis and clusters in serial blood samples from patients with metastatic breast cancer in a prospective observational cohort
    Sara Jansson
    Pär-Ola Bendahl
    Anna-Maria Larsson
    Kristina E. Aaltonen
    Lisa Rydén
    BMC Cancer, 16
  • [44] Prognostic impact of circulating tumor cell apoptosis and clusters in serial blood samples from patients with metastatic breast cancer in a prospective observational cohort
    Jansson, Sara
    Bendahl, Par-Ola
    Larsson, Anna-Maria
    Aaltonen, Kristina E.
    Ryden, Lisa
    BMC CANCER, 2016, 16
  • [45] Results from plasmaMATCH trial treatment cohort C: A phase II trial of capivasertib plus fulvestrant in ER positive breast cancer patients with an AKT1 mutation identified via ctDNA screening (CRUK/15/010)
    Roylance, Rebecca
    Kilburn, Lucy
    Kernaghan, Sarah
    Wardley, Andrew M.
    Macpherson, Iain
    Baird, Richard D.
    Stephens, Peter
    Oikonomidou, Olga
    Braybrooke, Jeremy P.
    Tuthill, Mark
    Abraham, Jacinta
    Winter, Matthew C.
    Kingston, Belinda
    Wilkinson, Katie
    Ring, Alistair
    Bliss, Judith M.
    Turner, Nicholas
    CANCER RESEARCH, 2020, 80 (04)
  • [46] PITX2 DNA-Methylation: Predictive versus Prognostic Value for Anthracycline-Based Chemotherapy in Triple-Negative Breast Cancer Patients
    Napieralski, Rudolf
    Schricker, Gabriele
    Auer, Gert
    Aubele, Michaela
    Perkins, Jonathan
    Magdolen, Viktor
    Ulm, Kurt
    Hamann, Moritz
    Walch, Axel
    Weichert, Wilko
    Kiechle, Marion
    Wilhelm, Olaf G.
    BREAST CARE, 2021, 16 (05) : 523 - 531
  • [47] Is it possible to predict the efficacy of a combination of cetuximab plus docetaxel in patients with operable, triple negative breast cancer (TNBC)? Final biomarker results from a phase II neoadjuvant trial
    Nabholtz, J-M
    Mouret-Reynier, M-A
    Abrial, C.
    Dauplat, M-M
    Radosevic-Robin, N.
    Van Praagh, I.
    Servent, V.
    Jacquin, J-P
    Bourcier, A-, V
    Del Piano, F.
    Dubray-Longeras, P.
    Nayl, B.
    Kwiatkoswki, F.
    Cayre, A.
    Uhrhammer, N.
    Bidet, Y.
    Chalabi, N.
    Bignon, Y-J
    Chollet, P.
    Penault-Llorca, F.
    CANCER RESEARCH, 2013, 73
  • [48] Impact of body mass index (BMI) on the predictive and prognostic value of stromal tumor-infiltrating lymphocytes (sTIL) in triple-negative breast cancer (TNBC) patients treated with neoadjuvant chemotherapy (NACT)
    Desmedt, Christine
    Richard, Francois
    Jongen, Lynn
    Hamy-Petit, Anne-Sophie
    Wildiers, Hans
    Ardui, Jan
    Punie, Kevin
    Smeets, Ann
    Berteloot, Patrick
    Vergote, Ignace
    Lae, Maricl
    Decroze, Diane
    Meseure, Didier
    Reyal, Fabien
    Biganzoli, Elia
    Neven, Patrick
    Floris, Giuseppe
    CANCER RESEARCH, 2020, 80 (04)
  • [49] Triple negative (TNBC) metastatic breast cancer (MBC) patients (pts): Is chemotherapy (CHT) choice influenced by adjuvant (adj) treatments? Results from the GIM-13 AMBRA study
    Mustacchi, Giorgio
    Beano, Alessandra
    Fabi, Alessandra
    Livi, Lorenzo
    Bernardo, Antonio
    Riccardi, Ferdinando
    Marchetti, Paolo
    Garrone, Ornella
    Diodati, Lucrezia
    Biganzoli, Laura
    Giordano, Monica
    Turletti, Anna
    Blasi, Livio
    Milani, Andrea
    Natoli, Clara
    Riemma, Marta
    D'Alonzo, Alessia
    Arpino, Grazia
    Pronzato, Paolo
    Cazzaniga, Marina E.
    CANCER RESEARCH, 2020, 80 (04)
  • [50] Breast MRI May Identify Patients that Benefit from Oncolytic Therapy in a Novel Phase I Trial Combining Neoadjuvant Talimogene Laherparepvec (TVEC) with ACT Chemotherapy in Patients with Triple Negative Breast Cancer (TNBC)
    Rothermel, L. D.
    Khazai, L.
    Mooney, B.
    Soliman, H. H.
    Czerniecki, B. J.
    ANNALS OF SURGICAL ONCOLOGY, 2019, 26 : S92 - S92
12345